RSV fusion: time for a new model
- PMID: 23518574
- PMCID: PMC3705301
- DOI: 10.3390/v5030873
RSV fusion: time for a new model
Abstract
In this review we propose a partially hypothetical model of respiratory syncytial virus (RSV) binding and entry to the cell that includes the recently discovered RSV receptor nucleolin, in an attempt to stimulate further inquiry in this research area. RSV binding and entry is likely to be a two-step process, the first involving the attachment of the virus to the cell membrane, which may be enhanced by electrostatic interactions with cellular glycoproteins/heparin and the viral G protein, and the second involving fusion to the cell membrane mediated by the viral F protein and a specific cellular fusion receptor. With our recent discovery of nucleolin as a functional fusion receptor for RSV, comes the possibility of a number of new approaches to the development of novel strategies for RSV prophylaxis and therapy, as well as raising some new questions concerning the pathobiology of RSV infection and tropism.
Figures


Similar articles
-
The RSV fusion receptor: not what everyone expected it to be.Microbes Infect. 2012 Nov;14(13):1205-10. doi: 10.1016/j.micinf.2012.07.015. Epub 2012 Jul 31. Microbes Infect. 2012. PMID: 22884716 Review.
-
Respiratory syncytial virus receptor expression in the mouse and viral tropism.Histol Histopathol. 2015 Apr;30(4):401-11. doi: 10.14670/HH-30.401. Epub 2014 Nov 6. Histol Histopathol. 2015. PMID: 25374027 Review.
-
Respiratory syncytial virus prolifically infects N2a neuronal cells, leading to TLR4 and nucleolin protein modulations and RSV F protein co-localization with TLR4 and nucleolin.J Biomed Sci. 2018 Feb 10;25(1):13. doi: 10.1186/s12929-018-0416-6. J Biomed Sci. 2018. PMID: 29427996 Free PMC article.
-
Single-Stranded Oligonucleotide-Mediated Inhibition of Respiratory Syncytial Virus Infection.Front Immunol. 2020 Dec 8;11:580547. doi: 10.3389/fimmu.2020.580547. eCollection 2020. Front Immunol. 2020. PMID: 33363532 Free PMC article.
-
IGF1R is an entry receptor for respiratory syncytial virus.Nature. 2020 Jul;583(7817):615-619. doi: 10.1038/s41586-020-2369-7. Epub 2020 Jun 3. Nature. 2020. PMID: 32494007
Cited by
-
Immunoinformatics-Aided Analysis of RSV Fusion and Attachment Glycoproteins to Design a Potent Multi-Epitope Vaccine.Vaccines (Basel). 2022 Aug 24;10(9):1381. doi: 10.3390/vaccines10091381. Vaccines (Basel). 2022. PMID: 36146460 Free PMC article.
-
Challenges and opportunities in developing respiratory syncytial virus therapeutics.J Infect Dis. 2015 Mar 15;211 Suppl 1(Suppl 1):S1-S20. doi: 10.1093/infdis/jiu828. J Infect Dis. 2015. PMID: 25713060 Free PMC article.
-
Human respiratory syncytial virus non-structural protein NS1 modifies miR-24 expression via transforming growth factor-β.J Gen Virol. 2015 Nov;96(11):3179-3191. doi: 10.1099/jgv.0.000261. J Gen Virol. 2015. PMID: 26253191 Free PMC article.
-
Respiratory syncytial virus (RSV) entry is inhibited by serine protease inhibitor AEBSF when present during an early stage of infection.Virol J. 2017 Aug 17;14(1):157. doi: 10.1186/s12985-017-0824-3. Virol J. 2017. PMID: 28818113 Free PMC article.
-
Human Respiratory Syncytial Virus: Infection and Pathology.Semin Respir Crit Care Med. 2016 Aug;37(4):522-37. doi: 10.1055/s-0036-1584799. Epub 2016 Aug 3. Semin Respir Crit Care Med. 2016. PMID: 27486734 Free PMC article. Review.
References
-
- Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., O'Brien K.L., Roca A., Wright P.F., Bruce N., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet. 2010;375:1545–1555. doi: 10.1016/S0140-6736(10)60206-1. - DOI - PMC - PubMed
-
- Blount R.E., Jr., Morris J.A., Savage R.E. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc. Soc. Exp. Biol. Med. 1956;92:544–549. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical